Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413765 | 0.88 | TGFBR1 (0.52) | TGFBR1MAPK14PIK3CDPIK3CAPI4KA | |
| SCHEMBL450076 | 0.86 | TGFBR1 (0.52) | TGFBR1MAPK14PIK3CDPIK3CAPI4KA | |
| SCHEMBL412299 | 0.85 | TGFBR1 (0.49) | TGFBR1MAPK14PIK3CDPIK3CAPI4KA | |
| SCHEMBL415611 | 0.83 | TGFBR1 (0.52) | TGFBR1MAPK14PIK3CDPIK3CAPI4KA | |
| SCHEMBL409987 | 0.83 | TGFBR1 (0.47) | TGFBR1MAPK14PIK3CDPIK3CAPI4KA | |
| SCHEMBL5956505 | 0.81 | TGFBR1 (0.55) | TGFBR1MAPK14PIK3CDPIK3CAPI4KA | |
| SCHEMBL6409107 | 0.80 | AR (0.47) | TGFBR1PIK3CAKDM4EALOX15L3MBTL1 | |
| SCHEMBL5956633 | 0.79 | TGFBR1 (0.54) | TGFBR1MAPK14KDM4EALDH1A1CYP3A4 | |
| SCHEMBL18236266 | 0.79 | TGFBR1 (0.60) | TGFBR1MAPK14PIK3CDPIK3CAPI4KA | |
| SCHEMBL18230394 | 0.77 | TGFBR1 (0.58) | TGFBR1MAPK14PIK3CDPIK3CAPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | claimed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | claimed |
| JP-2004524302-A | — | — | 2004-08-12 | — | — | JP | claimed |
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | claimed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | claimed |
| EP-1355870-A1 | THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | claimed |
| WO-2002062753-A1 | THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | claimed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010033906-A2 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | TGFBR1, TGFB1, TGFBR2 | TGFBR1 1/4885MAPK14 3537/4885PIK3CD 3894/4885 |
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885MAPK14 297/4885PIK3CD 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.